Correspondence 0001104659-23-062753 from AGILE THERAPEUTICS INC (AGRX, AGXRW) (CIK 0001261249)
AGILE THERAPEUTICS INC (AGRX, AGXRW) (CIK 0001261249)
Date: May 19, 2023 · CIK: 0001261249 · Accession: 0001104659-23-062753
AI Filing Summary & Sentiment
File numbers found in text: 333-271249
Letter
Agile Therapeutics, Inc.
500 College Road East, Suite 310
Princeton, New Jersey 08540
May 19, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Agile Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-271249
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Agile Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 (as amended, the “Registration Statement”) be accelerated to Monday, May 22, 2023, at 3:00 p.m., Eastern Time, or as soon as thereafter practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Bryan S. Keighery of Morgan, Lewis & Bockius LLP at (617) 341-7269.
Thank you very much.
Very truly yours,
Agile Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Agile Therapeutics, Inc.
500 College Road East, Suite 310
Princeton, New Jersey 08540
May 19, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Agile Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-271249
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 the Rules
and Regulations promulgated under the Securities Act of 1933, as amended, Agile Therapeutics, Inc. (the “Company”) hereby
requests that the effectiveness of the above-captioned Registration Statement on Form S-1 (as amended, the “Registration Statement”)
be accelerated to Monday, May 22, 2023, at 3:00 p.m., Eastern Time, or as soon as thereafter practicable.
Once the Registration Statement
has been declared effective, please orally confirm that event with Bryan S. Keighery of Morgan, Lewis & Bockius LLP at (617) 341-7269.
Thank you very much.
Very truly yours,
Agile Therapeutics, Inc.
By:
/s/ Alfred Altomari
Name:
Alfred Altomari
Title:
Chief Executive Officer